Last reviewed · How we verify
vehicle of loteprednol etabonate
vehicle of loteprednol etabonate is a Corticosteroid Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 3 development for Treatment of postoperative inflammation and pain following ocular surgery.
Loteprednol etabonate is a corticosteroid that works by inhibiting the inflammatory response.
Loteprednol etabonate is a corticosteroid that works by inhibiting the inflammatory response. Used for Treatment of postoperative inflammation and pain following ocular surgery.
At a glance
| Generic name | vehicle of loteprednol etabonate |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by suppressing the production of inflammatory mediators, such as prostaglandins and leukotrienes, which are involved in the inflammatory process. This leads to a reduction in inflammation and swelling. Loteprednol etabonate is a prodrug that is converted to its active form, loteprednol, which then exerts its anti-inflammatory effects.
Approved indications
- Treatment of postoperative inflammation and pain following ocular surgery
Common side effects
- Increased intraocular pressure
Key clinical trials
- Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (PHASE2)
- LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE2)
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vehicle of loteprednol etabonate CI brief — competitive landscape report
- vehicle of loteprednol etabonate updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about vehicle of loteprednol etabonate
What is vehicle of loteprednol etabonate?
How does vehicle of loteprednol etabonate work?
What is vehicle of loteprednol etabonate used for?
Who makes vehicle of loteprednol etabonate?
What drug class is vehicle of loteprednol etabonate in?
What development phase is vehicle of loteprednol etabonate in?
What are the side effects of vehicle of loteprednol etabonate?
What does vehicle of loteprednol etabonate target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of postoperative inflammation and pain following ocular surgery
- Compare: vehicle of loteprednol etabonate vs similar drugs
- Pricing: vehicle of loteprednol etabonate cost, discount & access